In DAYBREAK for wet AMD, what are the potential implications and upsides for KSI-501? Topline data: Q3 2026 Noninferiority study Better efficacy • Q3 2026 – Year 1 topline data evaluating Q4W/Q8W KSI-501 in wet AMD • Potential efficacy upside • Better vision gains than anti-VEGF monotherapy aflibercept with good OCT control • Note that bispecific inhibition of IL-6 and VEGF in the APEX Phase 1b study has shown that KSI-101, a bispecific anti-IL-6, VEGF trap, provides rapid and meaningful vision gains and rapid and powerful anatomical improvement in very sick patients • Strong and immediate disease control • Immediate disease control in the loading phase (closing the ‘immediacy gap’*), Wet AMD DAYBREAK KSI-501 38 Quadrant of core unmet need